Drugs / Methenamine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01657448 | Jun → Nov 2016 | urethral syndrome | EMS | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03379389 | Mar 2018 → May 2019 | urinary tract infection | Fundação Educacional Serra dos Órgãos | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06810687 | Jan 2025 → Jul 2027 expected | urinary tract infection | Atlantic Health System | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT05658874 Background | Dec 2022 → Dec 2024 | interstitial cystitis, levator syndrome | Jocelyn Fitzgerald | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Methenamine | “Methenamine” NCT02099240 ↗ |
| Route | Oral | “Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days” NCT01657448 ↗ |